Grunstein RR, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (TRIUMPH-1-OSA, TRIUMPH-2-OSA). N Engl J Med, 2026

PMID 42904878

Two double-blind placebo-controlled phase 3 trials (Eli Lilly), adults with moderate-to-severe OSA and BMI >=27: 243 without and 448 with type 2 diabetes, 80 weeks. AHI difference vs placebo with 9 and 12 mg: -24.4 and -21.9 events/h (no diabetes), -14.4 and -15.1 (diabetes). Weight -12.5 to -22.2% and -12.1 to -18.5% vs -4.8% and -5.6%. Investigational, not approved.